{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:19:22Z","timestamp":1789010362885,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,8,3]]},"DOI":"10.1038\/s41416-021-01379-w","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T06:03:29Z","timestamp":1621317809000},"page":"372-379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Low-fat dietary pattern and breast cancer mortality by metabolic syndrome components: a secondary analysis of the Women\u2019s Health Initiative (WHI) randomised trial"],"prefix":"10.1038","volume":"125","author":[{"given":"Kathy","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron K.","family":"Aragaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian L.","family":"Neuhouser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8901-4462","authenticated-orcid":false,"given":"Juhua","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bette","family":"Caan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Snetselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne E.","family":"Mortimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn E.","family":"Manson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candyce","family":"Kroenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerryn","family":"Reding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Rohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan T.","family":"Chlebowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"1379_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/jama.295.6.629","volume":"295","author":"RL Prentice","year":"2006","unstructured":"Prentice, R. L., Caan, B., Chlebowski, R. T., Patterson, R., Kuller, L. H., Ockene, J. K. et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women\u2019s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 295, 629\u2013642 (2006).","journal-title":"JAMA"},{"key":"1379_CR2","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1200\/JCO.2016.72.0326","volume":"35","author":"RT Chlebowski","year":"2017","unstructured":"Chlebowski, R. T., Aragaki, A. K., Anderson, G. L., Thomson, C. A., Manson, J. E., Simon, M. S. et al. Low-fat dietary pattern and breast cancer mortality in the Women\u2019s Health Initiative randomized controlled trial. J. Clin. Oncol. 35, 2919\u20132926 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1379_CR3","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.19.00435","volume":"38","author":"RT Chlebowski","year":"2020","unstructured":"Chlebowski, R. T., Aragaki, A. K., Anderson, G. L., Pan, K., Neuhouser, M. L., Manson, J. E. et al. Dietary modification and breast cancer mortality: long-term follow-up of the Women\u2019s Health Initiative randomized trial. J. Clin. Oncol. 38, 1419\u20131428 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1379_CR4","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KG Alberti","year":"2009","unstructured":"Alberti, K. G., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640\u20131645 (2009).","journal-title":"Circulation"},{"key":"1379_CR5","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1097\/GME.0b013e31828ce95d","volume":"20","author":"K Esposito","year":"2013","unstructured":"Esposito, K., Chiodini, P., Capuano, A., Bellastella, G., Maiorino, M. I., Rafaniello, C. et al. Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause 20, 1301\u20131309 (2013).","journal-title":"Menopause"},{"key":"1379_CR6","doi-asserted-by":"publisher","first-page":"189384","DOI":"10.1155\/2014\/189384","volume":"2014","author":"R Bhandari","year":"2014","unstructured":"Bhandari, R., Kelley, G. A., Hartley, T. A. & Rockett, I. R. Metabolic syndrome is associated with increased breast cancer risk: a systematic review with meta-analysis. Int. J. Breast Cancer 2014, 189384 (2014).","journal-title":"Int. J. Breast Cancer"},{"key":"1379_CR7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10549-017-4263-z","volume":"164","author":"AE Lohmann","year":"2017","unstructured":"Lohmann, A. E., Ennis, M., Taylor, S. K. & Goodwin, P. J. Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls. Breast Cancer Res. Treat. 164, 451\u2013460 (2017).","journal-title":"Breast Cancer Res. Treat."},{"key":"1379_CR8","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1002\/cncr.30104","volume":"122","author":"CM Dieli-Conwright","year":"2016","unstructured":"Dieli-Conwright, C. M., Wong, L., Waliany, S., Bernstein, L., Salehian, B. & Mortimer, J. E. An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy. Cancer 122, 2646\u20132653 (2016).","journal-title":"Cancer"},{"key":"1379_CR9","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1158\/1055-9965.EPI-10-0230","volume":"19","author":"T Bjorge","year":"2010","unstructured":"Bjorge, T., Lukanova, A., Jonsson, H., Tretli, S., Ulmer, H., Manjer, J. et al. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol. Biomark. Prev. 19, 1737\u20131745 (2010).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"1379_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/ijc.31344","volume":"143","author":"WG Gathirua-Mwangi","year":"2018","unstructured":"Gathirua-Mwangi, W. G., Song, Y., Monahan, P. O., Champion, V. L. & Zollinger, T. W. Associations of metabolic syndrome and C-reactive protein with mortality from total cancer, obesity-linked cancers and breast cancer among women in NHANES III. Int. J. Cancer 143, 535\u2013542 (2018).","journal-title":"Int. J. Cancer"},{"key":"1379_CR11","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1002\/cncr.31230","volume":"124","author":"MS Simon","year":"2018","unstructured":"Simon, M. S., Beebe-Dimmer, J. L., Hastert, T. A., Manson, J. E., Cespedes Feliciano, E. M., Neuhouser, M. L. et al. Cardiometabolic risk factors and survival after breast cancer in the Women\u2019s Health Initiative. Cancer 124, 1798\u20131807 (2018).","journal-title":"Cancer"},{"key":"1379_CR12","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.metabol.2012.04.007","volume":"61","author":"ML Neuhouser","year":"2012","unstructured":"Neuhouser, M. L., Howard, B., Lu, J., Tinker, L. F., Van Horn, L., Caan, B. et al. A low-fat dietary pattern and risk of metabolic syndrome in postmenopausal women: the Women\u2019s Health Initiative. Metab.: Clin. Exp. 61, 1572\u20131581 (2012).","journal-title":"Metab.: Clin. Exp."},{"key":"1379_CR13","doi-asserted-by":"publisher","first-page":"e181212","DOI":"10.1001\/jamaoncol.2018.1212","volume":"4","author":"RT Chlebowski","year":"2018","unstructured":"Chlebowski, R. T., Aragaki, A. K., Anderson, G. L., Simon, M. S., Manson, J. E., Neuhouser, M. L. et al. Association of low-fat dietary pattern with breast cancer overall survival: a secondary analysis of the Women\u2019s Health Initiative randomized clinical trial. JAMA Oncol. 4, e181212 (2018).","journal-title":"JAMA Oncol."},{"key":"1379_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/oxfordjournals.aje.a113804","volume":"119","author":"MJ Stampfer","year":"1984","unstructured":"Stampfer, M. J., Willett, W. C., Speizer, F. E., Dysert, D. C., Lipnick, R., Rosner, B. et al. Test of the National Death Index. Am. J. Epidemiol. 119, 837\u2013839 (1984).","journal-title":"Am. J. Epidemiol."},{"key":"1379_CR15","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/GME.0000000000000189","volume":"21","author":"JM Jackson","year":"2014","unstructured":"Jackson, J. M., DeFor, T. A., Crain, A. L., Kerby, T. J., Strayer, L. S., Lewis, C. E. et al. Validity of diabetes self-reports in the Women\u2019s Health Initiative. Menopause 21, 861\u2013868 (2014).","journal-title":"Menopause"},{"key":"1379_CR16","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/JCO.19.01472","volume":"37","author":"K Visvanathan","year":"2019","unstructured":"Visvanathan, K., Fabian, C. J., Bantug, E., Brewster, A. M., Davidson, N. E., DeCensi, A. et al. Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J. Clin. Oncol. 37, 3152\u20133165 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1379_CR17","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"97","author":"B Fisher","year":"2005","unstructured":"Fisher, B., Costantino, J. P., Wickerham, D. L., Cecchini, R. S., Cronin, W. M., Robidoux, A. et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. 97, 1652\u20131662 (2005).","journal-title":"J. Natl. Cancer Inst."},{"key":"1379_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","volume":"16","author":"J Cuzick","year":"2015","unstructured":"Cuzick, J., Sestak, I., Cawthorn, S., Hamed, H., Holli, K., Howell, A. et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 16, 67\u201375 (2015).","journal-title":"Lancet Oncol."},{"key":"1379_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S1470-2045(14)71184-2","volume":"16","author":"RT Chlebowski","year":"2015","unstructured":"Chlebowski, R. T. IBIS-I tamoxifen update: maturity brings questions. Lancet Oncol. 16, 7\u20139 (2015).","journal-title":"Lancet Oncol."},{"key":"1379_CR20","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","volume":"364","author":"PE Goss","year":"2011","unstructured":"Goss, P. E., Ingle, J. N., Ales-Martinez, J. E., Cheung, A. M., Chlebowski, R. T., Wactawski-Wende, J. et al. Exemestane for breast-cancer prevention in postmenopausal women. N. Engl. J. Med. 364, 2381\u20132391 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1379_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","volume":"395","author":"J Cuzick","year":"2020","unstructured":"Cuzick, J., Sestak, I., Forbes, J. F., Dowsett, M., Cawthorn, S., Mansel, R. E. et al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet 395, 117\u2013122 (2020).","journal-title":"Lancet"},{"key":"1379_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0140-6736(86)90729-4","volume":"1","author":"J Cuzick","year":"1986","unstructured":"Cuzick, J., Wang, D. Y. & Bulbrook, R. D. The prevention of breast cancer. Lancet 1, 83\u201386 (1986).","journal-title":"Lancet"},{"key":"1379_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/bjc.2013.756","volume":"110","author":"CA Purdie","year":"2014","unstructured":"Purdie, C. A., Quinlan, P., Jordan, L. B., Ashfield, A., Ogston, S., Dewar, J. A. et al. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br. J. Cancer 110, 565\u2013572 (2014).","journal-title":"Br. J. Cancer"},{"key":"1379_CR24","doi-asserted-by":"crossref","unstructured":"Dauphine C., Moazzez A., Neal J. C., Chlebowski R. T. & Ozao-Choy J. Single hormone receptor-positive breast cancers have distinct characteristics and survival. Ann. Surg. Oncol. 27, 4687\u20134694 (2020).","DOI":"10.1245\/s10434-020-08898-5"},{"key":"1379_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13098-019-0514-y","volume":"12","author":"P Li","year":"2020","unstructured":"Li, P., Wang, T., Zeng, C., Yang, M., Li, G., Han, J. et al. Association between metabolic syndrome and prognosis of breast cancer: a meta-analysis of follow-up studies. Diabetol. Metab. Syndr. 12, 10 (2020).","journal-title":"Diabetol. Metab. Syndr."},{"key":"1379_CR26","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1093\/jn\/nxz107","volume":"149","author":"RL Prentice","year":"2019","unstructured":"Prentice, R. L., Aragaki, A. K., Howard, B. V., Chlebowski, R. T., Thomson, C. A., Van Horn, L. et al. Low-fat dietary pattern among postmenopausal women influences long-term cancer, cardiovascular disease, and diabetes outcomes. The. J. Nutr. 149, 1565\u20131574 (2019).","journal-title":"J. Nutr."},{"key":"1379_CR27","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/ajh\/hpv196","volume":"29","author":"MA Allison","year":"2016","unstructured":"Allison, M. A., Aragaki, A. K., Ray, R. M., Margolis, K. L., Beresford, S. A., Kuller, L. et al. A randomized trial of a low-fat diet intervention on blood pressure and hypertension: tertiary analysis of the WHI dietary modification trial. Am. J. Hypertens. 29, 959\u2013968 (2016).","journal-title":"Am. J. Hypertens."},{"key":"1379_CR28","doi-asserted-by":"publisher","first-page":"nzaa021","DOI":"10.1093\/cdn\/nzaa021","volume":"4","author":"L Van Horn","year":"2020","unstructured":"Van Horn, L., Aragaki, A. K., Howard, B. V., Allison, M. A., Isasi, C. R., Manson, J. E. et al. Eating pattern response to a low-fat diet intervention and cardiovascular outcomes in normotensive women: the Women\u2019s Health Initiative. Curr. Dev. Nutr. 4, nzaa021 (2020).","journal-title":"Curr. Dev. Nutr."},{"key":"1379_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0007114514003341","volume":"113","author":"M Siervo","year":"2015","unstructured":"Siervo, M., Lara, J., Chowdhury, S., Ashor, A., Oggioni, C. & Mathers, J. C. Effects of the dietary approach to stop hypertension (DASH) diet on cardiovascular risk factors: a systematic review and meta-analysis. Br. J. Nutr. 113, 1\u201315 (2015).","journal-title":"Br. J. Nutr."},{"key":"1379_CR30","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S0140-6736(98)00379-1","volume":"353","author":"S Pocock","year":"1999","unstructured":"Pocock, S. & White, I. Trials stopped early: too good to be true? Lancet 353, 943\u2013944 (1999).","journal-title":"Lancet"},{"key":"1379_CR31","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1001\/jama.294.17.2203","volume":"294","author":"VM Montori","year":"2005","unstructured":"Montori, V. M., Devereaux, P. J., Adhikari, N. K., Burns, K. E., Eggert, C. H., Briel, M. et al. Randomized trials stopped early for benefit: a systematic review. JAMA 294, 2203\u20132209 (2005).","journal-title":"JAMA"},{"key":"1379_CR32","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.nut.2012.12.021","volume":"29","author":"F Shirani","year":"2013","unstructured":"Shirani, F., Salehi-Abargouei, A. & Azadbakht, L. Effects of dietary approaches to stop hypertension (DASH) diet on some risk for developing type 2 diabetes: a systematic review and meta-analysis on controlled clinical trials. Nutrition 29, 939\u2013947 (2013).","journal-title":"Nutrition"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01379-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01379-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01379-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T15:15:55Z","timestamp":1658330155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01379-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8,3]]}},"alternative-id":["1379"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01379-w","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,18]]},"assertion":[{"value":"28 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The WHI project was reviewed and approved by the Fred Hutchinson Cancer Research Center (Fred Hutch) IRB in accordance with the U.S. Department of Health and Human Services regulations at 45 CFR 46 (approval number: IR# 3467-EXT). Participants provided written informed consent to participate. Additional consent to review medical records was obtained through signed written consent. Fred Hutch has an approved FWA on file with the Office for Human Research Protections (OHRP) under assurance number 0001920. The trial was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The following data will be made available beginning 1 July 2022: the identified participant data and data dictionary (information about data sharing for the Women\u2019s Health Initiative can be found at ). For these analyses, data will be publicly available two years after the publication of this paper. The following supporting documents are available: statistical\/analytical and informed consent form ().","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Rowan T. Chlebowski is a consultant for Novartis, AstraZeneca, Genentech, Merck, Immunomedics, and Puma and received honorarium from Novartis and AstraZeneca. None of the other authors report any competing interests related to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The WHI program is supported by the National Heart, Lung and Blood Institute, National Institutes of Health, Department of Health and Human Services through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32 and 44221. HHSN268201600003C, HHSN268201600004C and R25CA203650 also partially supported the development of this paper.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}